Active Ingredient History
Allopurinol riboside is a metabolite of allopurinol, a xanthine oxidase inhibitor indicated for the management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. Allopurinol riboside is not an inhibitor of xanthine oxidase. Allopurinol riboside is commonly thought to be directly synthesized by purine nucleoside phosphorylase (PNP) in vivo. Allopurinol riboside competitively inhibits the action of PNP on inosine in vitro. Allopurinol riboside potently inhibits growth in vitro of promastigotes of Leishmania species. Patients with American cutaneous leishmaniasis who received allopurinol riboside had clinical improvement. In addition, allopurinol riboside demonstrated some effectivity against Trypanosoma cruzi infections in animals. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acute Coronary Syndrome (Phase 4)
Angina Pectoris (Phase 3)
Angina, Stable (Phase 4)
Arthritis (Phase 2)
Bipolar Disorder (Phase 4)
Blood Pressure (Phase 2)
Burkitt Lymphoma (Phase 2)
Cardiomyopathy, Dilated (Phase 1/Phase 2)
Cardiovascular Diseases (Phase 4)
Colitis, Ulcerative (Phase 3)
Coronary Artery Disease (Phase 4)
Deficiency Diseases (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 4)
Diabetic Neuropathies (Phase 3)
Essential Hypertension (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fasting (Phase 1)
Fetal Hypoxia (Phase 3)
Gout ()
Graft vs Host Disease (Phase 1)
Hamartoma (Phase 2)
Hand-Foot Syndrome (Phase 2)
Healthy Volunteers (Phase 1)
Heart Disease Risk Factors (Phase 1)
Heart Diseases (Phase 4)
Heart Failure (Phase 4)
Heart Failure, Diastolic (Phase 2)
Hematologic Diseases (Phase 2)
HIV Infections (Phase 3)
Hypertension (Phase 4)
Hypertrophy, Left Ventricular (Phase 4)
Hyperuricemia (Phase 4)
Hypoxia-Ischemia, Brain (Phase 3)
Infant, Newborn, Diseases (Phase 3)
Inflammation (Phase 3)
Inflammatory Bowel Diseases (Phase 1)
Ischemic Stroke (Phase 4)
Kidney Calculi (Phase 2)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 4)
Leukemia ()
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Plasma Cell (Phase 2)
Leukemia, Prolymphocytic (Phase 2)
Liver Diseases (Phase 2)
Lymphoma ()
Lymphoma, B-Cell (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Mania (Phase 4)
Metabolic Syndrome (Phase 2)
Multiple Myeloma (Phase 2)
Musculoskeletal Diseases (Phase 3)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Myocardial Ischemia (Phase 4)
Neoplasms (Phase 3)
Neoplasms, Plasma Cell (Phase 2)
Neuroprotection (Phase 3)
Obesity (Phase 3)
Ovarian Neoplasms (Phase 2)
Peripheral Arterial Disease (Phase 4)
Prediabetic State (Phase 3)
Prehypertension (Phase 2/Phase 3)
Psychotic Disorders (Phase 4)
Renal Insufficiency (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Reperfusion Injury (Phase 3)
Salts (Phase 1)
Sarcopenia (Phase 4)
Schizophrenia (Phase 4)
Sleep Apnea, Obstructive (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Sprains and Strains (Phase 3)
Tuberculosis (Phase 1)
Tumor Lysis Syndrome (Phase 3)
Urination Disorders (Phase 2)
Urolithiasis (Phase 4)
Vasoconstriction (Phase 1)
Vasodilation (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue